<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/AB8CCB0D-EFF3-4A96-A9BB-7BEE6AFB8AEF"><gtr:id>AB8CCB0D-EFF3-4A96-A9BB-7BEE6AFB8AEF</gtr:id><gtr:name>Cypralis Limited</gtr:name><gtr:address><gtr:line1>FYFIELD BUSINESS AND RESEARCH PARK , FYFIELD ROAD</gtr:line1><gtr:city>ONGAR</gtr:city><gtr:postCode>CM5 0GS</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AB8CCB0D-EFF3-4A96-A9BB-7BEE6AFB8AEF" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>AB8CCB0D-EFF3-4A96-A9BB-7BEE6AFB8AEF</gtr:id><gtr:name>Cypralis Limited</gtr:name><gtr:address><gtr:line1>FYFIELD BUSINESS AND RESEARCH PARK , FYFIELD ROAD</gtr:line1><gtr:city>ONGAR</gtr:city><gtr:postCode>CM5 0GS</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>191953.0</gtr:offerGrant><gtr:projectCost>319921.0</gtr:projectCost></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>109064.0</gtr:offerGrant><gtr:projectCost>109064.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/DD56E19D-764A-45E7-9DBA-A8B034CDA66D"><gtr:id>DD56E19D-764A-45E7-9DBA-A8B034CDA66D</gtr:id><gtr:firstName>carol</gtr:firstName><gtr:surname>austin</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=102854"><gtr:id>183B8A04-48F0-497D-9DB0-F92220560A3F</gtr:id><gtr:title>Selective Inhibitors of Cyclophilin D for the treatment of Acute Pancreatitis</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Collaborative R&amp;D</gtr:grantCategory><gtr:grantReference>102854</gtr:grantReference><gtr:abstractText>The current project is directed at the development of a new therapy to treat acute pancreatitis (AP). AP is an extremely painful disease that is most often associated with gall stones, excessive alcohol intake and obesity and is currently treated in the hospital with supportive therapy only. However, a significant proportion of patients with AP can progress to more life threatening conditions due to the pancreas inflammation affecting other body organs. This inflammation is the result of cell death in the pancreas and new treatments that can prevent this have been shown to be effective at preventing AP in animal studies. Cypralis has discovered new compounds that can act on pancreatic cells and stop the disease from progressing. These compounds are being developed by Cypralis as the first disease-modifying treatments for AP. This project is to improve the manufacturing process of the compounds, to develop an intravenous injection of the drug and to show the drugs work and are safe in a number of animal models of AP.</gtr:abstractText><gtr:fund><gtr:end>2017-12-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2017-01-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>301017</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">102854</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>